TFF Pharmaceuticals Inc. - TFFP Enterprise Value to Sales Volume

Public company logo of tffpharma.com (TFFP)

Does TFF Pharmaceuticals (TFFP) have a future now that the business liquidation is nearly complete? Optimism was driven by US-based CMO outsourcing sites developing inhalation drugs, but the EV-to-revenue multiple indicates a dangerous overvaluation. The value of captures the metric level amid risks of technological substitution and the slow adoption of freeze-drying by partners, which is crashing the capitalization.

TFF Pharmaceuticals Inc. - TFFP Enterprise Value-to-Revenue Ratio (period 07/04/2022 - 11/20/2026)

TFF Pharmaceuticals Inc. - analytical breakdowns and key metrics (TFFP)

Initial company analysis:tffpharma.com TFFP
Product sample of TFF Pharmaceuticals, Inc.

The EV/Sales metric determines the total enterprise value, including debt, per unit of revenue, allowing for an assessment of the market premium paid for the generated cash flow. By analyzing historical EV/Sales levels, an investor can correlate the valuation of TFF Pharmaceuticals (TFFP) with the potential of its innovative technology for converting drugs into powder form for inhalation, which expands partnerships with global pharma behemoths.

Competitor analysis

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Company Value to Revenue SNYR|Enterprise Value-to-Revenue Multiple rallybio.com RLYB|EV/Sales Multiple LEXX|PULM (Pulmatrix, Inc.) - Business Value to Revenue|Pheton Holdings - Company Value to Revenue|EV/Sales Multiple Aptorum Group Limited APM|LYRA: Company Value to Revenue|IBO: Enterprise Value-to-Revenue Ratio|TNFA: EV/Sales Multiple|YCBD: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio PainReform Ltd|CYTO (altamiratherapeutics.com) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple LIPO|OPTN - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio pieris.com PIRS|Business Value to Revenue PROC|PTPI - Enterprise Value-to-Revenue Ratio|Qilian International Holding (QLI) - Company Value to Revenue|SLRN: EV/Sales Multiple